ArticleFrontiers in cardiovascular medicine2025
The relationship between different anticoagulation monitoring indicators and heparin doses in adult patients with extracorporeal cardiopulmonary resuscitation.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Achieving optimal systemic anticoagulation in patients undergoing extracorporeal membrane oxygenation (ECMO) requires precise titration, posing a significant clinical challenge. This study aims to explore the relationship between various anticoagulation monitoring parameters and heparin dosing in adult patients undergoing extracorporeal cardiopulmonary resuscitation (ECPR). Methods: A retrospective analysis was conducted on 40 ECPR patients, who were categorized into either the activated clotting time (ACT)-target group or the activated partial thromboplastin time (aPTT)-target group. Anticoagulation monitoring parameters, including aPTT, corresponding ACT, and heparin doses, were collected. Continuous variables are expressed as mean ± SD and compared using Student's Results: Of the 40 patients, 16 (40%) died and 24 (60%) survived. Twelve patients (30%) experienced severe bleeding events, while five (12.5%) developed thrombotic complications. Compared with the ACT-target group, the aPTT-target group had higher platelet counts (PLT) and lower blood flow levels ( Conclusion: Heparin dosing exhibited a stronger correlation with aPTT than with ACT, and blood flow emerged as an important monitoring parameter. Comprehensive anticoagulation monitoring strategies should be employed to evaluate heparin efficacy in ECMO-treated ECPR patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.